References
- Grant S, Clissold S. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310–344.
- Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88:1058–1066.
- Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1–8.
- Srivatsan V, Dasgupta AK, Kale P, Datla RR, Soni D, Patel M, Patel R, Mavadhiya C. Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. J Chromatogr A 2004;1031:307–313.
- Product monograph Sporanox. Available online at: http://www.janssen-ortho.com/joi/pdf_files/sporanoxcaps_e.pdf, accessed 07 May 2010.
- Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA. Practice guidelines for 83 diseases caused by Aspergillus. Clin Infect Dis 2000;30:6696–709.
- Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005;56:17–87.
- Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug formulation dissolution and in vivo bioavailability. Pharm Res 1995;12:413–420.
- Food and Drug Administration. Guidance for industry: bioanalytical method validation (May 2001). Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf, accessed 07 May 2010.
- Food and Drug Administration. Guidance for industry: statistical approaches to establishing bioequivalence. (January 2001). Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf, accessed 07 May 2010.